Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trialSabino De Placido, Edoardo Biondi, Lucia Del Mastro et al.|The Lancet Oncology|2018Cited by 88
The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast CancerStefania Gori, Alessandro Inno, Fabio Puglisi et al.|Clinical Breast Cancer|2019Cited by 15
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational studyFrancesca Sofia Di Lisa, Enzo Veltri, Eriseld Krasniqi et al.|Frontiers in Oncology|2023Cited by 9
Outcome of patients (pts) with brain metastases (BMs) from HER2-positive breast cancer (BC) treated with lapatinib plus capecitabine (LC).Giulio Metro, Stefania Gori, Jennifer Foglietta et al.|Journal of Clinical Oncology|2010Cited by 1